Search

Your search keyword '"Wei, Andrew"' showing total 126 results

Search Constraints

Start Over You searched for: Author "Wei, Andrew" Remove constraint Author: "Wei, Andrew" Publisher elsevier inc. Remove constraint Publisher: elsevier inc.
126 results on '"Wei, Andrew"'

Search Results

3. Venetoclax–based low intensity therapy in molecular failure of NPM1-mutated AML

5. Sorafenib plus intensive chemotherapy in newly diagnosed FLT3-ITD AML: a randomized, placebo-controlled study by the ALLG

6. Somatic mutational landscape of hereditary hematopoietic malignancies caused by germline variants in RUNX1, GATA2, and DDX41

7. Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML

9. Acquired mutations in BAX confer resistance to BH3-mimetic therapy in acute myeloid leukemia

10. Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial

12. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN

13. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data

14. Idasanutlin plus cytarabine in relapsed or refractory acute myeloid leukemia: results of the MIRROS trial

17. Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL

19. An MRD-stratified pediatric protocol is as deliverable in adolescents and young adults as in children with ALL

20. Clinical MDR1 inhibitors enhance Smac-mimetic bioavailability to kill murine LSCs and improve survival in AML models

21. Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial

24. MDS-476 Sabatolimab (MBG453) Combination Treatment Regimens for Patients With Higher-Risk Myelodysplastic Syndromes (HR-MDS): The Myelodysplastic Syndromes Studies in the STIMULUS Immuno-Myeloid Clinical Trial Program

26. AML-432 Overall Survival (OS) by IDH2 Mutant Allele (R140 or R172) in Patients With Late-Stage, Mutant-IDH2 Relapsed/Refractory Acute Myeloid Leukemia (AML) Treated With Enasidenib or Conventional Care Regimens (CCR) in the Randomized, Open-Label, Phase 3 IDHENTIFY Trial

29. Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell population

31. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

34. An agenda to advance research in myelodysplastic syndromes: a TOP 10 priority list from the first international workshop in MDS

35. Characteristics and outcomes of patients with acute promyelocytic leukemia and extreme hyperleukocytosis at presentation

36. Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes

37. TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype

38. Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy

39. Long-term follow-up of VIALE-C in patients with untreated AML ineligible for intensive chemotherapy

41. Olutasidenib (FT-2102) Induces Durable Complete Remissions in Patients with Relapsed/Refractory mIDH1 Acute Myeloid Leukemia. Results from a Planned Interim Analysis of a Phase 2 Pivotal Clinical Trial

43. Somatic Mutational Landscape of Hereditary Hematopoietic Malignancies Associated with Germline Variants in RUNX1, GATA2 and DDX41

44. High Deliverability of a Midostaurin Triplet Regimen Incorporating Venetoclax and Low Dose Cytarabine in Non-Adverse Cytogenetic Risk Acute Myeloid Leukaemia: A Sub-Analysis of the Australasian Leukaemia Lymphoma Group (ALLG) Intervene Study

45. ALLG AMLM26 Phase 1B/2 Study Investigating Novel Therapies to Target Early Relapse and Clonal Evolution As Pre-Emptive Therapy in AML (INTERCEPT): A Multi-Arm, Precision-Based, Recursive, Platform Trial

46. Preliminary Safety and Efficacy of Bgb-11417, a Novel Bcl-2 Inhibitor, in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML)

48. Molecular MRD Assessment Is Strongly Prognostic in Patients with NPM1 Mutated AML Receiving Venetoclax Based Non-Intensive Therapy

Catalog

Books, media, physical & digital resources